Back
4D Molecular Therapeutics 10K Form
Sell
47
FDMT
4D Molecular Therapeutics
Last Price:
$4.21
Seasonality Move:
-13.73%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-03-25 | 10K | FDMT/4D Molecular Therapeutics Annual |
Receive FDMT News And Ratings
See the #1 stock for the next 7 days that we like better than FDMT
FDMT Financial Statistics
Sales & Book Value
| Annual Sales: | $37K |
|---|---|
| Cash Flow: | $-48.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $10.14 |
| Price / Book: | 0.42 |
Profitability
| EPS (TTM): | -3.18000 |
|---|---|
| Net Income (TTM): | $-176.4M |
| Gross Margin: | -- |
| Return on Equity: | -32.41% |
| Return on Assets: | -30.11% |
4D Molecular Therapeutics Earnings Forecast
Key 4D Molecular Therapeutics Financial Ratios
-
The Research & Development expenses have been 381,889.19% of Revenue.
-
The Net Earning history of FDMT is -434,778.38% of Total Revenues.
-
Per Share Earnings over the last 8 years have been positive in 2 years.
4D Molecular Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | FDMT |
| CUSIP: | 35104E |
| Website: | 4dmoleculartherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 12.36 |
| Quick Ratio: | 11.95 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
FDMT Technical Analysis vs Fundamental Analysis
Sell
47
4D Molecular Therapeutics (FDMT)
is a Sell
Is 4D Molecular Therapeutics a Buy or a Sell?
-
4D Molecular Therapeutics stock is rated a SellThe current 4D Molecular Therapeutics [FDMT] share price is $4.24. The Score for FDMT is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.